Drugs / KNT-0916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06800196 | Mar 2025 → Sep 2027 expected | — | KinoTeck Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KNT-0916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06800196 ↗ |
| Action | Inhibit | “inhibitor of FGFR2” NCT06800196 ↗ |
| Route | Oral | “KNT-0916 is an oral inhibitor of FGFR2.” NCT06800196 ↗ |
| Target | FGFR2 | “inhibitor of FGFR2” NCT06800196 ↗ |